Pliant Therapeutics (PLRX) is a clinical-stage biopharmaceutical company with no approved products and no revenue-generating operations. Under a liquidation lens, recovery posture is determined almost entirely by the cash and liquid investment balance versus the liability stack. The MFFAIS system reports latest CLV/LLV/OLV all at $1.42 million, which is materially lower than what would be expected for a company of this stage and suggests the system may be capturing a residual or stale figure rather than the full Q1 2026 balance sheet — the TAG_CONTEXT array is empty, meaning no XBRL-tagged balance sheet values were extractable from this filing submission for analysis. The filing body provided consists entirely of the risk factors section and exhibit list from the 10-Q for the period ended March 31, 2026; no financial statements, balance sheet, or footnote disclosures are present in the truncated input. Accordingly, specific asset and liability line items cannot be independently verified or haircut. From prior filing context (10-K for FY2025, filed March 11, 2026), the company had completed two workforce restructurings in 2025 totaling approximately $6.3 million in cash charges, with the December 2025 tranche of $2.5 million accrued but unpaid at year-end. The company carries an operating lease (the Oyster Point Lease) with a weighted-average remaining term of 5.0 years and a 9.3% discount rate as of December 31, 2025, representing a material fixed obligation. Annual operating lease cost was $6.0 million in FY2025. The company disclosed it is evaluating sublease options or early lease termination, indicating potential incremental termination liability. Key pipeline developments between filings: the BEACON-IPF Phase 2b trial for bexotegrast was discontinued in March 2025 following a DSMB safety review, and in June 2025 the company announced full discontinuation of bexotegrast development in IPF, eliminating the lead program entirely. The company's sole remaining clinical asset is PLN-101095, an integrin inhibitor in early-stage oncology trials. The company had U.S. federal NOL carryforwards of $485.9 million and state NOLs of $398.2 million as of December 31, 2025; these have zero liquidation value. An ATM facility for up to $50 million was established March 30, 2026. No long-term debt is disclosed. The liquidation recovery posture is negative to minimal: all intangible and pipeline value haircuts to zero, the lease obligation survives at face value, and the accrued restructuring liability plus any remaining severance obligations reduce recoverable cash. Equity recovery depends entirely on the cash and short-term investment balance surviving the liability stack, which is not quantifiable from the inputs provided. Filing does not separately tag any balance sheet items in XBRL in this submission.
▼ Community Notes